NovoNordisk Gets CDSCO Panel Nod To Study anti-diabetic FDC Cagrilinitide,Semaglutide

This came after the drug maker Novo-Nordisk presented the proposed Phase IIIa trial protocol no. NN9838-4608, Version 03 dated 24Jun2022 (REDEFINE) for FDCs anti-diabetic drug Cagrilinitide plus Semaglutide before the committee.

The nod is subjected to condition that the firm should submit the trial safety and efficacy data to the committee for review and further initiation of the extension phase.

Cagrilintide is a long-acting amylin analogue intended for once-weekly treatment being developed by Novo Nordisk, as a subcutaneous formulation, for the treatment of obesity and non-alcoholic steatohepatitis.

Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.

At recent SEC meeting for endocrinology and metabolism held on 9th September 2022,the expert panel reviewed the proposal presented by the drug marker Novo-Nordisk for the FDCs anti-diabetic drug Cagrilinitide plus Semaglutide Phase IIIa trial protocol no.NN9838-4608,Version 03 dated 24Jun2022 (REDEFINE)